Thursday, 5 November 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 25, 2025

Drilling Programs Define New Zones as Gold Still Targets $5,000

View original at globenewswire.com
Drilling Programs Define New Zones as Gold Still Targets $5,000 Issued on behalf of Lake Victoria Gold Ltd. VANCOUVER, British Columbia, Nov…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Core hole LADD031 demonstrates that the BIF is still thick and well mineralized at 570m depth toward the projected northwest edge of Adumbi deposit

    80% confidence

  • Gold will reach $5,055 per ounce by late 2026 driven by sustained central bank accumulation

    80% confidence

  • Lake Victoria Gold is executing dual-track strategy: developing Imwelo toward first production within 12 months of construction while maintaining optionality through Barrick's fully funded exploration

    80% confidence

  • The Q3 results from Barrick highlight a systematic and technically strong approach to unlocking the Tembo geology

    80% confidence

  • Gold will reach $5,055 per ounce by late 2026 driven by sustained central bank accumulation

    80% confidence

  • The high-grade results exceeded expectations and demonstrate exceptional potential of flagship project which ranks as one of highest-grade undeveloped open pittable gold deposits in Canada

    80% confidence

  • Q3 2025 was highly successful with construction of Stage 3 Plant under budget, multiple financial records, and company is in strongest financial position in history

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com
Drilling Programs Define New Zones as Gold Still Targets $5,000 — Source | Via News | ViaNews EU